Market Cap 370.48M
Revenue (ttm) 0.00
Net Income (ttm) -15.79M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 160,400
Avg Vol 416,476
Day's Range N/A - N/A
Shares Out 13.86M
Stochastic %K 65%
Beta 1.50
Analysts Strong Sell
Price Target $47.50

Company Profile

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company also develops FLAMINGO-01, which is in Phase III clinical trial designed to evaluate the safety and efficacy...

Industry: Biotechnology
Sector: Healthcare
Phone: 832 819 3232
Address:
Building 14, 3992 Bluebonnet Dr., Stafford, United States
msgbrdinfo
msgbrdinfo Mar. 15 at 9:33 PM
$GLSI We are probably jinxed by the nonstop pumping. Message boards with this much nonstop "we're gonna soon be rich" posting often result in share price disappointment. 🤮
1 · Reply
TheinvestmetABCD
TheinvestmetABCD Mar. 15 at 4:21 AM
$GLSI game of patience 🫣 Thanks god days pass quick lol
1 · Reply
doc123266
doc123266 Mar. 15 at 2:14 AM
$GLSI Snehal has sent up reliable signals throughout the duration of this trial. Announcement of abstracts is yet one more. Not to say really big deal data or news but also not announcing failure. This is home stretch.
1 · Reply
Rolltide2020
Rolltide2020 Mar. 14 at 7:45 PM
2 · Reply
doc123266
doc123266 Mar. 14 at 3:17 PM
0 · Reply
Toontje1
Toontje1 Mar. 14 at 2:49 PM
$GLSI Greenwich is being primed for a massive breakthrough. The doctors are in it for the medical milestone and to provide the credibility needed for Big Pharma and a major buyout
0 · Reply
Alwaysdiversify
Alwaysdiversify Mar. 14 at 12:51 PM
$GLSI "Recruiting a Steering Committee (SC) with the pedigree found in the FLAMINGO-01 trial is uncommon but highly strategic for a pre-revenue biotech. While many small biotechs use Scientific Advisory Boards, the level of global leadership represented in the GLSI SC—comprising heads of major oncology programs and international research networks—is typically seen in much larger pharmaceutical companies. Selection Criteria: Top-tier oncologists generally only join SCs for trials they believe have a high probability of clinical success or represent a significant scientific breakthrough, as their reputation is tied to the trial's outcome. Strategic Oversight: Unlike an Advisory Board, this SC has actual voting power and decision-making authority over the trial's protocol and execution. Efficiency Gap: Small teams often lack internal depth; an elite SC bridges this by providing "Big Pharma" decision-making capabilities, helping to avoid costly protocol errors or enrollment bottlenecks."
1 · Reply
Alwaysdiversify
Alwaysdiversify Mar. 14 at 12:19 PM
$GLSI Here's another tidbit from Google Gemini..... "Based on their current social media activity and specific roles within the project, the Steering Committee members most likely to post updates regarding GLSI-100 and the FLAMINGO-01 trial are: Dr. Mothaffar F. Rimawi (Chair): As the Steering Committee Chair, he is the primary scientific voice for the trial. He is active on X (@mfrimawi) and LinkedIn, frequently sharing milestone updates and conference presentations related to his research at Baylor College of Medicine. Dr. Hope S. Rugo: She is a highly influential figure in the breast cancer community with a significant following on X (@hoperugo). She is known for live-tweeting key data releases and "breaking news" from major conferences like the upcoming AACR Annual Meeting. Dr. William J. Gradishar: He maintains an active presence on X (@DrWGradishar), where he often shares peer-reviewed abstracts and clinical trial designs, including those for the FLAMINGO-01 study."
1 · Reply
Alwaysdiversify
Alwaysdiversify Mar. 14 at 12:13 PM
$GLSI Another tidbit courtesy of Google Gemini....... "Based on their current social media activity and specific roles within the project, most likely Steering Committee members to post updates regarding GLSI-100 and the FLAMINGO-01 trial. Dr. Mothaffar F. Rimawi (Chair): As the Steering Committee Chair, he is the primary scientific voice for the trial. He is active on X (@mfrimawi) and LinkedIn, frequently sharing milestone updates and conference presentations related to his research at Baylor College of Medicine. Dr. Hope S. Rugo: She is a highly influential figure in the breast cancer community with a significant following on X (@hoperugo). She is known for live-tweeting key data releases and "breaking news" from major conferences like the upcoming AACR Annual Meeting. Dr. William J. Gradishar: He maintains an active presence on X (@DrWGradishar), where he often shares peer-reviewed abstracts and clinical trial designs, including those for the FLAMINGO-01 study."
0 · Reply
CrabCakes
CrabCakes Mar. 14 at 10:39 AM
$GLSI Just to clarify, correct me if this is incorrect. The Submission of the title for the abstract is not big news in itself. This is scheduled for all the presenters. Not a biggie. What is potentially big news is the content of the presentation. GLTA
1 · Reply
Latest News on GLSI
Greenwich LifeSciences Provides Global Update on FLAMINGO-01

Apr 3, 2025, 8:00 AM EDT - 1 year ago

Greenwich LifeSciences Provides Global Update on FLAMINGO-01


Greenwich LifeSciences Partners with GIM in Italy

Nov 26, 2024, 6:00 AM EST - 1 year ago

Greenwich LifeSciences Partners with GIM in Italy


Greenwich LifeSciences Provides Update on Corporate Events

Nov 18, 2024, 6:00 AM EST - 1 year ago

Greenwich LifeSciences Provides Update on Corporate Events


Greenwich LifeSciences Set to Join Russell 2000 Index Again

Jun 26, 2024, 7:33 AM EDT - 1 year ago

Greenwich LifeSciences Set to Join Russell 2000 Index Again


Greenwich LifeSciences Provides Year End Update

Dec 29, 2022, 6:48 AM EST - 3 years ago

Greenwich LifeSciences Provides Year End Update


Greenwich LifeSciences: Persevering CEO And Interesting Data

Sep 6, 2022, 5:40 PM EDT - 3 years ago

Greenwich LifeSciences: Persevering CEO And Interesting Data


Here's Why Greenwich Lifesciences Shares Are Popping Off Today

Jul 12, 2022, 1:18 PM EDT - 3 years ago

Here's Why Greenwich Lifesciences Shares Are Popping Off Today


msgbrdinfo
msgbrdinfo Mar. 15 at 9:33 PM
$GLSI We are probably jinxed by the nonstop pumping. Message boards with this much nonstop "we're gonna soon be rich" posting often result in share price disappointment. 🤮
1 · Reply
TheinvestmetABCD
TheinvestmetABCD Mar. 15 at 4:21 AM
$GLSI game of patience 🫣 Thanks god days pass quick lol
1 · Reply
doc123266
doc123266 Mar. 15 at 2:14 AM
$GLSI Snehal has sent up reliable signals throughout the duration of this trial. Announcement of abstracts is yet one more. Not to say really big deal data or news but also not announcing failure. This is home stretch.
1 · Reply
Rolltide2020
Rolltide2020 Mar. 14 at 7:45 PM
2 · Reply
doc123266
doc123266 Mar. 14 at 3:17 PM
0 · Reply
Toontje1
Toontje1 Mar. 14 at 2:49 PM
$GLSI Greenwich is being primed for a massive breakthrough. The doctors are in it for the medical milestone and to provide the credibility needed for Big Pharma and a major buyout
0 · Reply
Alwaysdiversify
Alwaysdiversify Mar. 14 at 12:51 PM
$GLSI "Recruiting a Steering Committee (SC) with the pedigree found in the FLAMINGO-01 trial is uncommon but highly strategic for a pre-revenue biotech. While many small biotechs use Scientific Advisory Boards, the level of global leadership represented in the GLSI SC—comprising heads of major oncology programs and international research networks—is typically seen in much larger pharmaceutical companies. Selection Criteria: Top-tier oncologists generally only join SCs for trials they believe have a high probability of clinical success or represent a significant scientific breakthrough, as their reputation is tied to the trial's outcome. Strategic Oversight: Unlike an Advisory Board, this SC has actual voting power and decision-making authority over the trial's protocol and execution. Efficiency Gap: Small teams often lack internal depth; an elite SC bridges this by providing "Big Pharma" decision-making capabilities, helping to avoid costly protocol errors or enrollment bottlenecks."
1 · Reply
Alwaysdiversify
Alwaysdiversify Mar. 14 at 12:19 PM
$GLSI Here's another tidbit from Google Gemini..... "Based on their current social media activity and specific roles within the project, the Steering Committee members most likely to post updates regarding GLSI-100 and the FLAMINGO-01 trial are: Dr. Mothaffar F. Rimawi (Chair): As the Steering Committee Chair, he is the primary scientific voice for the trial. He is active on X (@mfrimawi) and LinkedIn, frequently sharing milestone updates and conference presentations related to his research at Baylor College of Medicine. Dr. Hope S. Rugo: She is a highly influential figure in the breast cancer community with a significant following on X (@hoperugo). She is known for live-tweeting key data releases and "breaking news" from major conferences like the upcoming AACR Annual Meeting. Dr. William J. Gradishar: He maintains an active presence on X (@DrWGradishar), where he often shares peer-reviewed abstracts and clinical trial designs, including those for the FLAMINGO-01 study."
1 · Reply
Alwaysdiversify
Alwaysdiversify Mar. 14 at 12:13 PM
$GLSI Another tidbit courtesy of Google Gemini....... "Based on their current social media activity and specific roles within the project, most likely Steering Committee members to post updates regarding GLSI-100 and the FLAMINGO-01 trial. Dr. Mothaffar F. Rimawi (Chair): As the Steering Committee Chair, he is the primary scientific voice for the trial. He is active on X (@mfrimawi) and LinkedIn, frequently sharing milestone updates and conference presentations related to his research at Baylor College of Medicine. Dr. Hope S. Rugo: She is a highly influential figure in the breast cancer community with a significant following on X (@hoperugo). She is known for live-tweeting key data releases and "breaking news" from major conferences like the upcoming AACR Annual Meeting. Dr. William J. Gradishar: He maintains an active presence on X (@DrWGradishar), where he often shares peer-reviewed abstracts and clinical trial designs, including those for the FLAMINGO-01 study."
0 · Reply
CrabCakes
CrabCakes Mar. 14 at 10:39 AM
$GLSI Just to clarify, correct me if this is incorrect. The Submission of the title for the abstract is not big news in itself. This is scheduled for all the presenters. Not a biggie. What is potentially big news is the content of the presentation. GLTA
1 · Reply
sentinelles
sentinelles Mar. 14 at 5:40 AM
$GLSI biotechnology company Greenwich LifeSciences
0 · Reply
Rolltide2020
Rolltide2020 Mar. 13 at 7:30 PM
$GLSI I feel strongly the title will include this type of bullish language. If we haven’t made it back to $30 by then, we may skip $30’s altogether.
0 · Reply
Stock_profit_03
Stock_profit_03 Mar. 13 at 7:29 PM
$GLSI Good luck to longs for next week. I hope to see shorts getting cooked
0 · Reply
cupandhandleguy
cupandhandleguy Mar. 13 at 4:36 PM
$GLSI Is it possible they drop news over the weekend? Not sure I wana hold cause of the war but don’t wana miss the pump!
2 · Reply
HoldGuy_GLSI
HoldGuy_GLSI Mar. 13 at 3:25 PM
$GLSI Always has one or two red days before to the moon
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Mar. 13 at 2:57 PM
$GLSI Volume is super light today-
1 · Reply
TheinvestmetABCD
TheinvestmetABCD Mar. 13 at 1:40 PM
$GLSI Lets get above $29 in the next few trading days and jump to new ATHs on the 17th of March!
1 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Mar. 13 at 12:46 PM
$GLSI Personally I do not think the stock will move with any more certainty after the disclosure of the abstarct titles. It will move after peers digest the abstract and if lucky we get published in one of the high profile publications like JAMA or ESMO.
3 · Reply
Kamal2020
Kamal2020 Mar. 13 at 10:35 AM
$GLSI Only 2 trading days before the title alert! I see 28$ barrier broken in these 2 days for smoothing sailing till 17th April. Have a target of 50-60$ by 16th April.
1 · Reply
Zyntax
Zyntax Mar. 13 at 8:13 AM
$GLSI What kind of share price are people expecting after 17th of April presentation? I assume they are significant.
1 · Reply
Zacharyk75
Zacharyk75 Mar. 13 at 2:19 AM
$GLSI up to 1500 shares now… ready for April
3 · Reply